Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
UCLA Center for Systems Biomedicine, David Geffen School of Medicine, Los Angeles, California.
F S Sci. 2022 Aug;3(3):269-278. doi: 10.1016/j.xfss.2022.02.005. Epub 2022 Feb 18.
To identify early follicular phase microribonucleic acids (miRNAs) that are altered in serum of women with endometriosis.
Case-control study.
Large university-affiliated in vitro fertilization center.
PATIENT(S): Women with (n = 21) and without (n = 24) endometriosis.
INTERVENTION(S): Serum samples were obtained from laparoscopy-confirmed patients with endometriosis.
MAIN OUTCOME MEASURE(S): The differential expression of serum miRNAs relative to controls was measured using the NanoString nCounter technology and validated by quantitative real-time polymerase chain reaction in an independent cohort of 27 patients with endometriosis and controls (n = 24). Microribonucleic acid target signaling pathways and genes were analyzed bioinformatically. A chemically modified stable miR-34-3p oligonucleotide was used to examine the effect on proliferation of VK2E6/E7 endometrial cells in vitro.
RESULT(S): Eighteen miRNAs were significantly up-regulated, and 1 miRNA (hsa-miR-34c-3p) was significantly down-regulated in the follicular phase of patients with endometriosis. The analysis of target signaling pathways using TargetScan predicted regulation of the mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, Hippo, adenosine monophosphate-activated protein kinase, transforming growth factor beta, and endometrial cancer pathways, which have been implicated in the pathogenesis of endometriosis, by these miRNAs. The analysis of sequence complementarity identified prostaglandin E2 receptor 4, interleukin 6 signal transducer, and polo-like kinase 4 genes as possible direct targets of hsa-miR-34-3p. DSDI-1, a chemically modified stable miR-34-3p oligonucleotide, reduced cell proliferation in VK2E6/E7 endometrial cells in vitro.
CONCLUSION(S): The follicular phase miRNA levels are altered in serum of women with endometriosis and may be useful as reproducible detection biomarkers for early diagnosis of endometriosis. hsa-miR-34-3p is significantly down-regulated in endometriosis, targets endometriosis genes, and reduces endometrial cell proliferation in vitro. These results support hsa-miR-34-3p as a potential therapeutic target in endometriosis.
鉴定在子宫内膜异位症女性的卵泡早期血清中发生改变的微小核糖核酸(miRNAs)。
病例对照研究。
大型大学附属体外受精中心。
患有子宫内膜异位症的女性(n=21)和无子宫内膜异位症的女性(n=24)。
从腹腔镜确认的子宫内膜异位症患者中获得血清样本。
使用 NanoString nCounter 技术测量血清 miRNA 与对照相比的差异表达,并在独立的 27 例子宫内膜异位症患者和对照(n=24)队列中通过定量实时聚合酶链反应进行验证。使用生物信息学分析微小核糖核酸靶信号通路和基因。使用化学修饰的稳定 miR-34-3p 寡核苷酸在体外检查对 VK2E6/E7 子宫内膜细胞增殖的影响。
在子宫内膜异位症患者的卵泡期,有 18 个 miRNA 显著上调,1 个 miRNA(hsa-miR-34c-3p)显著下调。使用 TargetScan 分析靶信号通路预测这些 miRNA 调节丝裂原活化蛋白激酶、磷酸肌醇 3-激酶/蛋白激酶 B、Hippo、腺苷单磷酸激活蛋白激酶、转化生长因子β和子宫内膜癌通路,这些通路与子宫内膜异位症的发病机制有关。序列互补分析确定前列腺素 E2 受体 4、白细胞介素 6 信号转导物和 Polo 样激酶 4 基因为 hsa-miR-34-3p 的可能直接靶标。化学修饰的稳定 miR-34-3p 寡核苷酸 DSDI-1 减少 VK2E6/E7 子宫内膜细胞在体外的增殖。
子宫内膜异位症女性的卵泡期 miRNA 水平发生改变,可能作为子宫内膜异位症早期诊断的可重复检测生物标志物。hsa-miR-34-3p 在子宫内膜异位症中显著下调,靶向子宫内膜异位症基因,并减少体外子宫内膜细胞增殖。这些结果支持 hsa-miR-34-3p 作为子宫内膜异位症的潜在治疗靶点。